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Abstract: A 72-year-old man who received warfarin for myocardial infarction (prothrombin time-international normalized ratio [PT-INR] 
controlled between 2.2 and 2.5) for 2 years. He developed lung cancer, underwent surgery, and received tegafur plus uracil (UFT) after 
1 month. After 2 months, he was admitted for hemoptysis and dyspnea. Chest radiography and computed tomography showed bilateral 
alveolar infiltration (PT-INR, 8.9). Bronchoalveolar lavage fluid (BALF) disclosed hemorrhagic features in sequential samples. And he 
was diagnosed with diffuse alveolar hemorrhage (DAH). A known interaction exists between fluoropyrimidines and warfarin. So, they 
were discontinued, and vitamin K was intravenously administered. One day later, the PT-INR returned to 1.14. The symptoms improved 
and, alveolar infiltration resolved after 2 weeks. Alveolar hemorrhage may be due to an interaction between UFT and warfarin. When 
fluoropyrimidines and warfarin are prescribed simultaneously, we recommend that PT-INR should be closely monitored.
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Introduction
DAH can occur as a manifestation of various   diseases.1 
Anticoagulant therapy is one of the causes of DAH. 
Elderly  individuals  may  have  many    coexisting 
  illnesses and are typically prescribed different types 
of drugs. Therefore, drug interactions are a problem 
associated with medication.
Fluoropyrimidines  (eg,  5-FU,  UFT,  TS-1,  and 
capecitabine) are used as anticancer agents. A known 
interaction  exists  between  fluoropyrimidines  and 
warfarin.2 Warfarin is an oral anticoagulant, which 
is  often  used  to  prevent  thromboembolic  compli-
cations  in  cardiovascular  diseases. They  are  well-
known to contribute to a large amount of inter-patient 
  variability  in  warfarin  metabolism,  which  appears 
to  be  related  to  genetic  polymorphisms  in  cyto-
chrome P-450 enzyme 2C9 (CYP2C9) and/or vita-
min K epoxide reductase complex 1 (VKORC1).3–5 
Therefore, we examined polymorphisms of CYP2C9 
and VKORC1 in this patient.
There  are  only  a  few  reports  discussing  DAH 
association with warfarin therapy.6,7 We report a case 
of DAH related to combination therapy using UFT 
and warfarin.
case Report
The patient was a 72-year-old man who presented 
with  hemoptysis  and  dyspnea.  He  had  been 
taking  200  mg  aspirin  daily,  200  mg  ticlopidine 
hydrochloride  daily  and  2  mg  warfarin  daily  for 
2 years for myocardial infarction after percutaneous 
coronary intervention. The PT-INR was controlled at 
2.2 to 2.5. He then developed lung adenocarcinoma 
(pT1N0M0 stage IA), and a right lower lobectomy 
was performed. The tumor was 2.5 cm in diameter. 
UFT  generally  improves  the  survival  rate  among 
patients with tumors 2 to 3 cm in diameter.8 Thus, one 
month after operation, he began taking 2 capsules of 
UFT (200 mg tegafur and 448 mg uracil) twice daily 
as an adjuvant therapy. After the operation, he did not 
consult a cardiovascular physician but continued the 
same doses of medicines.
Two months later, he was admitted to our hospital 
with  hemoptysis,  cough,  and  dyspnea.  Before  his 
symptoms  were  evaluated,  no  antibiotics  or  other 
drugs, such as those that affect the metabolism of 
vitamin K, were prescribed. On the other hand, he did 
not have diarrhea, so we speculated that his colonic 
flora and vitamin K absorption was normal.
The patient had previously been a smoker (smoking 
exposure,  100  pack-years)  and  he  had  chronic 
obstructive  pulmonary  disease  (GOLD  guideline 
stage II). Physical examination showed that he had 
many large purpuras on his limbs; his respiratory rate 
was 30 breaths/min; blood pressure, 109/58 mmHg; 
heart  rate,  76  beats/min;  and  body  temperature, 
37.0  °C.  Results  of  laboratory  investigations  were 
as follows: hemoglobin level, 7.5 g/dL; WBC count, 
8,100  cells/µL;  platelet  count,  213,000  cells/µL; 
PT-INR, 8.9. Basic biochemical profiles were normal. 
Myeloperoxidase  antineutrophil  cytoplasmic  auto-
antibody  (MPO-ANCA),  proteinase  3-ANCA 
(PR3-ANCA),  antiglomerular  basement  membrane 
antibody,  antinuclear  antibody,  and  anti–double-
stranded DNA antibody were all negative. The results 
of  urinalysis  were  within  a  normal  range.  Chest 
radiograph  showed  bilateral  alveolar  infiltration 
(Fig.  1).  Chest  computed  tomography  (CT)  scan 
showed bilateral ground-glass opacities and multiple 
low attenuation areas (Fig. 2). Pulse oximetry showed 
84% percutaneous O2 saturation, and oxygen therapy 
was begun. Fiberoptic bronchoscopy was performed. 
Figure 1. Chest radiograph showed bilateral alveolar infiltration.Alveolar Hemorrhage Associated with UFT and Warfarin
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Airways with blood were observed, but abnormality 
of bronchial mucosa was not found. BALF disclosed 
hemorrhagic  features  in  sequential  samples. 
Histopathological analysis of bloody BALF showed 
hemosiderin-filled  macrophages  (.20%  of  total 
alveolar macrophages), thereby confirming alveolar 
hemorrhage (Fig. 3). Because of the presence of tarry 
stools, gastrointestinal fiberscopy was conducted, and 
no abnormalities were found. UFT, warfarin, aspirin, 
and ticlopidine hydrochloride were discontinued, and 
10 mg vitamin K was administered intravenously. One 
day later, the PT-INR returned to 1.14. His symptoms 
gradually improved, and bilateral alveolar infiltration 
resolved after about 2 weeks (Fig. 4).
We  examined  genetic  polymorphisms  of  cyto- 
ch  rome P-450 enzyme 2C9 (CYP2C9) and   vitamin K 
epoxide reductase complex 1 (VKORC1), which can 
influence the management of warfarin therapy. The 
patient  had  no  polymorphisms  of  CYP2C9  but  a 
homozygous mutation was found in VKORC1. After 
prescribing warfarin, aspirin, and ticlopidine hydro-
chloride (with no UFT), the PT-INR was controlled 
at 2.2 (INR target range, 2.0–2.5). At follow-up visits, 
the patient remained asymptomatic.
Discussion
We report the case of a patient with DAH related to 
combination therapy of UFT and warfarin. The patient 
was prescribed 2 mg warfarin daily for 2 years; he 
had no bleeding episodes and PT-INR had been well-
controlled, in the range of 2 to 2.5. However, after 
UFT  was  started,  PT-INR  markedly  increased  to 
8.9. After DAH resolved, anticoagulant therapy was 
restarted, and PT-INR was controlled at 2.2. Thus, 
it is possible that an interaction exists between UFT 
and warfarin.
DAH can occur as a manifestation of various diseases 
such as Wegener’s granulomatosis, Henochschönlein 
purpura, microscopic polyangiitis, antiphospholipid 
antibody  syndrome,  and  Goodpasture’s  syndrome.1 
In this case, MPO-ANCA, PR3-ANCA, antiglomerular 
basement membrane antibody, antinuclear antibody, 
and  anti–double-stranded  DNA  antibody  were  all 
negative. However, a renal function test and urinalysis 
were normal. Therefore, we diagnosed this patient 
with drug-induced DAH.
DAH  can  occur  as  a  rare  complication  of 
  warfarin  therapy.6,7  To  our  knowledge,  this  is  the 
first case of DAH associated with UFT and   warfarin. 
Figure 2. Chest CT scan showed bilateral ground-glass opacities and 
multiple low attenuation areas.
Figure 3. Histopathological analysis of bloody bronchoalveolar lavage 
fluid showed hemosiderin-filled macrophages.
Figure 4. Chest CT scan showed bilateral alveolar infiltration resolved.Itoh et al
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Recently,  Saif  reported  that  patients  receiving 
concomitant capecitabine or fluorouracil (5-FU) and 
warfarin had altered coagulation parameters and con-
sequent bleeding, thus causing shock in some cases.2
Warfarin is an oral anticoagulant, which is often 
used  to  prevent  thromboembolic  complications  in 
cardiovascular diseases. They are well-known to con-
tribute to a large amount of inter-patient variability 
in warfarin metabolism, which appears to be related 
to  genetic  polymorphisms  in  CYP2C9  and/or 
VKORC1.3–5 CYP2C9 is a key enzyme in the hepatic 
metabolism  of  warfarin,  whereas  VKORC1  works 
to maintain sufficient vitamin K levels when dietary 
vitamin  K  is  limited.  The  VKORC1  homozygous 
mutation affects the high response to warfarin.
UFT  is  an  orally  available  drug  whose    activity 
is comparable to that of intravenously   administered 
5-FU  combined  with  folinic  acid.  Derivatives 
based on fluoropyrimidines (eg, 5-FU, UFT, TS-1, 
and  capecitabine)  are  used  for  the  management 
of    several  malignancies  such  as  lung,  pancreatic, 
upper  gastrointestinal,  and  breast  cancers.  Kato 
et al reported that UFT as a postoperative adjuvant 
  treatment, which can be used to improve the progno-
sis of patients with completely resected adenocarci-
noma (stage IB).8 UFT was administered in this case 
and such an effect of UFT was expected. Recently, 
results of an enzymatic study suggested that 5-FU has 
inhibitory effects against the activities of microsomal 
enzymes, including CYP2C.9
On  the  basis  of  results  of  recent  studies,  we 
speculated that genetic polymorphisms of CYP2C9 
and/or  VKORC1  are  mechanisms  of  interaction 
between  fluoropyrimidines  and  warfarin  in  our 
patient. Therefore, we examined polymorphisms of 
CYP2C9 and VKORC1 in this patient. The patient’s 
genotype was CYP2C9 *1/*1; thus, he did not have 
the  polymorphisms  of  CYP2C9,  but  did  have  a 
homozygous mutation of VKORC1 A/A.
The patient responded well to warfarin treatment. 
Additionally,  PT-INR  was  well-controlled  using  a 
small  amount  of  warfarin  for  therapy.  In  addition 
to the inhibitory effects of UFT on the activities of 
CYP2C9, DAH may be induced by a smaller dose 
of warfarin.
Our  patient  was  also  prescribed  aspirin  and 
ticlopidine hydrochloride. However, it is well known 
that there are no correlations between the metabolism 
of these drugs and CYP2C9 or VKORC1.   Moreover, 
after  re-administration  of  anticoagulants,  PT-INR 
was  controlled  (2.2),  and  the  patient  remained 
  asymptomatic. Thus, the interaction between warfarin 
and  another  anticoagulant  may  not  be  the  cause 
of DAH.
Recently,  a  report  described  polymorphisms  of 
CYPA6 associated with metabolism of 5-FU.10 The 
clearance of 5-FU observed in patients with 2 variant 
alleles was significantly lower than that in patients 
with  wild  type  alleles. We  did  not  assess  for  this 
mutation,  but  it  is  possible  that  our  patient  has 
the mutation.
The exact mechanism of these interactions remains 
unclear, and further investigation is necessary. When 
fluoropyrimidines  and  warfarin  are  prescribed 
simultaneously, we recommend that PT-INR should 
be closely monitored.
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